Summary
54 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $15.2M against $8.99M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 11 USD is left as net profit.
What to watch
- Revenue fell by 16% a year over the last 3 years.
- It earns only 3.0 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 0.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
Revenue fell by 7.1% a year over 5 years. Over the last 3 years it fell by 16% a year. Earnings per share fell by 13% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Research and development 3.9 USD
- Sales and administration 14 USD
- Taxes and other 2.4 USD
- Net profit 11 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 16.2 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.